Unlocking Blood-Purification Programs and DrugSorb-ATR's Regulatory Path with Cytosorbents Corporation

Cytosorbents Corporation (CTSO) discussed progress in blood-purification programs and DrugSorb-ATR's regulatory path. The company's CEO, Phillip Chan, and CFO, Peter Mariani, will address investors on the company's progress and future outlook. The presentation will cover the company's two key products, CytoSorbents and DrugSorb, which remove deleterious cytokines and drugs, respectively, from the blood. The company will also discuss its regulatory strategy for DrugSorb-ATR and its plans for navigating the evolving regulatory landscape.